Search bioRxiv⌕ Search

Biology subjects

Morten, K.

Publications and source records attributed to Morten, K..

2 recordsLinked to original sources

Metabolic Symbiosis between Oxygenated and Hypoxic Tumour Cells: An Agent-based Modelling Study

Deregulated metabolism is one of the hallmarks of cancer. It is well-known that tumour cells tend to metabolize glucose via glycolysis even when oxygen is available and mitochondrial respiration is functional. However, the lower energy efficiency of aerobic glycolysis with respect to mitochondrial respiration makes this behaviour, namely the Warburg effect, counter-intuitive, although it has now been recognized as a source of anabolic precursors. On the other hand, there is evidence that oxygenated tumour cells could be fuelled by exogenous lactate produced from glycolysis, and that glycolytic tumour cells export lactate to the environment. Using a multi-scale approach combining multi-agent modelling, diffusion-reaction and stoichiometric equations, we simulated these cell populations and their environment, and studied the metabolic co-operation between cells exposed to different oxygen concentration and nutrient abundance. The results show that the metabolic cooperation between cells reduces the depletion of environmental glucose, resulting in an overall advantage of using aerobic glycolysis. In addition, the environmental oxygen level was found to be decreased by the symbiosis, promoting a further shift towards anaerobic glycolysis. However, the oxygenated and hypoxic cell populations may gradually reach quasi-equilibrium. A sensitivity analysis based on Latin hypercube sampling and partial rank correlation shows that the symbiotic dynamics depends on properties of the specific cell such as the minimum glucose level needed for glycolysis. Our results suggest that strategies that block glucose transporters may be more effective than those blocking lactate intake transporters to reduce tumour growth by blocking lactate production. AUTHOR SUMMARYMetabolic alteration is one of the hallmarks of cancer and the well-known metabolic alteration of tumour cells is that cells prefer to do glycolysis over mitochondrial respiration even under well-oxygenated and functional mitochondrial conditions. On the other hand, there is evidence that oxygenated tumour cells could be fuelled by exogenous lactate produced from hypoxic glycolytic cells in which it can create a metabolic co-operation between oxygenated and hypoxic cell populations. This metabolic co-operation could allow tumour cells to economically share oxygen and glucose and promote tumour survival. Using a multi-scale approach combining multi-agent modelling, diffusion-reaction and stoichiometric equations, we studied this metabolic co-operation between different populations of cells, exposed to a changing microenvironment. We predict that the tumour environmental glucose depletion is decreased while the oxygen depletion is increased by this metabolic symbiosis, promoting a further shift towards glycolysis. Our results also show that blocking glucose transporters could be more effective than blocking lactate intake transporters, because the former would disrupt both glycolysis and lactate production, drastically reducing tumour growth.

systems biology↗

Acetyl-Leucine slows disease progression in lysosomal storage disorders

Acetyl-DL-leucine (ADLL) is a derivative of the branched chain amino acid leucine. In observational clinical studies ADLL improved symptoms of ataxia, in particular in patients with the lysosomal storage disorder (LSD), Niemann-Pick disease type C 1 (NPC1). Here, we investigated ADLL and its enantiomers acetyl-L-leucine (ALL) and acetyl-D-leucine (ADL) in symptomatic Npc1-/- mice and observed an improvement in ataxia with both enantiomers and ADLL. When ADLL and ALL were administered pre-symptomatically to Npc1-/- mice, both treatments delayed disease progression and extended life span, whereas ADL did not. These data are consistent with ALL being the neuroprotective enantiomer. Altered glucose and antioxidant metabolism were found to be implicated as one of the potential mechanisms of action of the L enantiomer in Npc1-/- mice. When miglustat and ADLL were used in combination significant synergy resulted. In agreement with these pre-clinical data, when NPC1 patients were evaluated after 12 months of ADLL treatment, rates of disease progression were slowed, with stabilisation or improvement in multiple neurological domains. A beneficial effect of ADLL on gait was also observed in this study in a mouse model of GM2 gangliosidosis (Sandhoff disease) and in Tay-Sachs and Sandhoff disease patients in individual-cases of off-label-use. Taken together, we have identified an unanticipated neuroprotective effect of acetyl-L-leucine and underlying mechanisms of action in LSDs, supporting its further evaluation in clinical trials in lysosomal disorders.

neuroscience↗